ARWR
Price
$16.83
Change
+$0.22 (+1.32%)
Updated
Jun 4, 02:08 PM (EDT)
Capitalization
2.29B
68 days until earnings call
COUR
Price
$9.08
Change
-$0.09 (-0.98%)
Updated
Jun 3 closing price
Capitalization
2.21B
50 days until earnings call
Interact to see
Advertisement

ARWR vs COUR

Header iconARWR vs COUR Comparison
Open Charts ARWR vs COURBanner chart's image
Arrowhead Pharmaceuticals
Price$16.83
Change+$0.22 (+1.32%)
Volume$100
Capitalization2.29B
Coursera
Price$9.08
Change-$0.09 (-0.98%)
Volume$1.39M
Capitalization2.21B
ARWR vs COUR Comparison Chart
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COUR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. COUR commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a StrongBuy and COUR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (ARWR: $16.61 vs. COUR: $9.08)
Brand notoriety: ARWR: Notable vs. COUR: Not notable
ARWR represents the Biotechnology, while COUR is part of the Miscellaneous Commercial Services industry
Current volume relative to the 65-day Moving Average: ARWR: 104% vs. COUR: 71%
Market capitalization -- ARWR: $2.29B vs. COUR: $2.21B
ARWR [@Biotechnology] is valued at $2.29B. COUR’s [@Miscellaneous Commercial Services] market capitalization is $2.21B. The market cap for tickers in the [@Biotechnology] industry ranges from $321.16B to $0. The market cap for tickers in the [@Miscellaneous Commercial Services] industry ranges from $80.94B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B. The average market capitalization across the [@Miscellaneous Commercial Services] industry is $5.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileCOUR’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • COUR’s FA Score: 0 green, 5 red.
According to our system of comparison, COUR is a better buy in the long-term than ARWR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 5 TA indicator(s) are bullish while COUR’s TA Score has 4 bullish TA indicator(s).

  • ARWR’s TA Score: 5 bullish, 4 bearish.
  • COUR’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ARWR is a better buy in the short-term than COUR.

Price Growth

ARWR (@Biotechnology) experienced а +8.07% price change this week, while COUR (@Miscellaneous Commercial Services) price change was +5.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.47%. For the same industry, the average monthly price growth was +5.26%, and the average quarterly price growth was -2.00%.

The average weekly price growth across all stocks in the @Miscellaneous Commercial Services industry was +0.80%. For the same industry, the average monthly price growth was +6.28%, and the average quarterly price growth was +7.29%.

Reported Earning Dates

ARWR is expected to report earnings on Aug 11, 2025.

COUR is expected to report earnings on Jul 24, 2025.

Industries' Descriptions

@Biotechnology (+6.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Miscellaneous Commercial Services (+0.80% weekly)

The sector produces general business services, and are not classified elsewhere. For example, FleetCor Technologies provides fuel cards and workforce payment products and services; Copart, Inc. provides online vehicle auction and remarketing services across various nations; Equifax Inc. collects and aggregates credit information on consumers and businesses worldwide, along with selling credit monitoring and fraud-prevention services. Many of the companies in this category have multi-billion market capitalizations.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($2.29B) and COUR($2.21B) have the same market capitalization . COUR YTD gains are higher at: 6.824 vs. ARWR (-11.649). COUR has higher annual earnings (EBITDA): -129.13M vs. ARWR (-580.69M). COUR has more cash in the bank: 722M vs. ARWR (553M). COUR has less debt than ARWR: COUR (6.6M) vs ARWR (525M). COUR has higher revenues than ARWR: COUR (636M) vs ARWR (2.5M).
ARWRCOURARWR / COUR
Capitalization2.29B2.21B104%
EBITDA-580.69M-129.13M450%
Gain YTD-11.6496.824-171%
P/E RatioN/AN/A-
Revenue2.5M636M0%
Total Cash553M722M77%
Total Debt525M6.6M7,959%
FUNDAMENTALS RATINGS
ARWR: Fundamental Ratings
ARWR
OUTLOOK RATING
1..100
21
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
60
P/E GROWTH RATING
1..100
2
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARWRCOUR
RSI
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
71%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
69%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 7 days ago
74%
Declines
ODDS (%)
Bearish Trend 29 days ago
84%
Bearish Trend 15 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COUR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFDMX36.800.41
+1.13%
DF Dent Midcap Growth Investor
MEICX49.60N/A
N/A
MFS Value C
MBAYX13.19N/A
N/A
MassMutual Balanced Svc
DBMZX28.43N/A
N/A
BNY Mellon Sm/Md Cp Gr Z
JDINX50.98-0.18
-0.35%
Janus Henderson Overseas N

COUR and

Correlation & Price change

A.I.dvisor indicates that over the last year, COUR has been loosely correlated with DNB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if COUR jumps, then DNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COUR
1D Price
Change %
COUR100%
-0.98%
DNB - COUR
48%
Loosely correlated
+0.11%
UDMY - COUR
48%
Loosely correlated
+1.99%
ARLO - COUR
46%
Loosely correlated
+1.38%
ATAI - COUR
45%
Loosely correlated
-5.62%
EVLV - COUR
33%
Poorly correlated
+1.86%
More